PRISMA 2020 vs PRISMA-ScR vs PRISMA-DTA vs PRISMA-NMA: Which Reporting Guideline Do You Need?

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is the standard for transparent reporting of systematic reviews. But PRISMA is not a single guideline — it is a family of reporting standards, each designed for a different type of review.

Using the wrong PRISMA variant is one of the most common reasons manuscripts receive editorial queries or desk rejections. This guide compares all four variants so you can identify the right one immediately.

The PRISMA Family at a Glance

Variant	Year	Applies To	Checklist Items	Flow Diagram
PRISMA 2020	2021	Standard systematic reviews and meta-analyses	27 items	Updated 2020 template
PRISMA-ScR	2018	Scoping reviews	20 essential + 2 optional	Modified for scoping
PRISMA-DTA	2018	Diagnostic test accuracy reviews	27 items (adapted)	DTA-specific
PRISMA-NMA	2015	Network meta-analyses	32 items (PRISMA + 5 NMA extensions)	Standard + network

PRISMA 2020 — The Standard

PRISMA 2020 replaced PRISMA 2009 as the primary reporting guideline for systematic reviews of interventions. It is the default for:

Pairwise reviews comparing one treatment to a control
Prognostic factor reviews
Reviews of observational studies
Most reviews that involve pairwise meta-analysis

Key Features

27-item checklist organized across title, abstract, introduction, methods, results, discussion, and other information (funding, registration, data availability).

Updated flow diagram with distinct sections for:

Identification from databases and registers
Identification from other methods (citation searching, grey literature)
Screening with reasons for exclusion at each stage
Included studies and reports

New in 2020 compared to 2009:

Explicit reporting of automation tools and AI used in the review process
Certainty of evidence assessment (GRADE) explicitly required
Data availability statement
Distinction between "studies" and "reports" (one study may produce multiple reports)
Registration and protocol reporting requirements strengthened

When to Use

Use PRISMA 2020 for any standard systematic review or meta-analysis that does not fall into the DTA, NMA, or scoping categories. If in doubt, PRISMA 2020 is the safe default.

PRISMA-ScR — For Scoping Reviews

PRISMA-ScR was developed because scoping reviews have a fundamentally different purpose than systematic reviews. They map the literature rather than synthesize effect estimates, and they do not assess study quality or certainty of evidence.

Key Differences from PRISMA 2020

Fewer checklist items: 20 essential items (vs 27 for PRISMA 2020), reflecting the simpler methodology
No quality assessment items: Since scoping reviews typically do not assess risk of bias, these items are absent
No synthesis items: No meta-analysis or certainty of evidence reporting
"Data charting" replaces "data extraction": The terminology reflects the descriptive nature of data collection
Two optional items: Critical appraisal and summary of evidence (optional because these are not standard in scoping review methodology)

Checklist Highlights

Item 1: Title must identify the report as a scoping review
Item 8: Eligibility criteria described using PCC (not PICOS)
Item 14: Data charting process described (iterative updates allowed)
Item 17: Results of individual sources presented
Item 20: Summary of evidence linked back to review objectives

When to Use

Use PRISMA-ScR when your review is a scoping review — that is, when you are mapping the breadth of literature on a topic rather than answering a specific clinical question with pooled data.

PRISMA-DTA — For Diagnostic Test Accuracy Reviews

Diagnostic test accuracy (DTA) reviews evaluate how well a diagnostic test identifies a target condition. The statistics, study designs, and reporting requirements are different enough from pairwise reviews that PRISMA 2020 alone is insufficient.

Key Differences from PRISMA 2020

DTA-specific methods items: Reporting of the index test, reference standard, and how discrepancies between them were handled
2x2 data: Results must include true positives, false positives, false negatives, and true negatives for each study
Bivariate meta-analysis: Standard pairwise forest plots are replaced by SROC (Summary Receiver Operating Characteristic) curves and coupled forest plots
QUADAS-2: Risk of bias reporting uses QUADAS-2 domains rather than RoB 2 domains
Different flow diagram: The DTA flow diagram accounts for the structure of DTA studies (verification, partial verification, differential verification)

Checklist Adaptations

Methods — Index test and reference standard: Full description of both, including how thresholds were defined
Methods — Synthesis: Description of bivariate or HSROC models used
Results — Test accuracy: Sensitivity and specificity (with 95% CI) for each study
Results — Synthesis: SROC curve with summary point and confidence/prediction regions

When to Use

Use PRISMA-DTA when your review evaluates the diagnostic accuracy of one or more tests against a reference standard. Common in radiology, laboratory medicine, and point-of-care testing research.

PRISMA-NMA — For Network Meta-Analyses

Network meta-analyses compare three or more interventions simultaneously. The additional complexity of indirect evidence, network geometry, and consistency assessment requires reporting beyond what PRISMA 2020 covers.

Key Differences from PRISMA 2020

PRISMA-NMA adds 5 extension items to the standard PRISMA checklist (32 total items):

Network geometry: Description and visualization of the treatment network, including which comparisons have direct evidence
Assessment of transitivity: How the authors verified that the transitivity assumption is reasonable
Methods for NMA: Statistical model used (frequentist vs Bayesian), handling of multi-arm trials, and approach to ranking treatments
Consistency assessment: Methods used to assess agreement between direct and indirect evidence (local and global tests)
Presentation of network results: League tables, ranking probabilities, and comparison-adjusted funnel plots

Additional Reporting Requirements

Network plot: A graph showing all interventions (nodes) and direct comparisons (edges) with node size and edge thickness reflecting the amount of evidence
League table: A matrix of all pairwise comparisons with effect estimates and confidence intervals
Rankograms or SUCRA/P-scores: Treatment ranking with uncertainty
Consistency results: Results of inconsistency tests (loop-specific or design-by-treatment interaction)

When to Use

Use PRISMA-NMA when your review compares three or more interventions using network meta-analysis methods. Even if you also present pairwise comparisons, the NMA extension items are necessary.

Side-by-Side Comparison

Feature	PRISMA 2020	PRISMA-ScR	PRISMA-DTA	PRISMA-NMA
Study type	Pairwise, prognostic	Scoping	Diagnostic accuracy	Network MA
Framework	PICOS	PCC	PICOS (adapted)	PICOS
Quality assessment	Required	Optional	Required (QUADAS-2)	Required
Meta-analysis	Pairwise	None	Bivariate	Network
GRADE	Required	Not applicable	GRADE-DTA	CINeMA
Flow diagram	PRISMA 2020	PRISMA-ScR	PRISMA-DTA	PRISMA 2020 + network
Unique items	Data availability, AI use	Data charting	Index test, reference standard	Network geometry, transitivity, consistency

Common Mistakes

Using PRISMA 2009 instead of PRISMA 2020 — The 2009 version is outdated. Journals increasingly require the 2020 update.
Using PRISMA 2020 for a scoping review — Scoping reviews have their own extension. Using the standard checklist leads to items that do not apply and missing items that do.
Skipping PRISMA-NMA extension items — Reporting a network meta-analysis with only PRISMA 2020 items leaves out critical information about network geometry, transitivity, and consistency.
Not including the flow diagram — All PRISMA variants require a flow diagram. Each has a specific template.
Mixing PRISMA variants within a single review — Use the one variant that matches your study type. Do not combine checklists.

Automatic PRISMA Selection in mapped

mapped eliminates the guesswork. When you select your study type during project creation:

Pairwise or Prognostic → PRISMA 2020 is enforced
Scoping → PRISMA-ScR is enforced
DTA → PRISMA-DTA is enforced
NMA → PRISMA-NMA is enforced

The platform generates the correct flow diagram variant, applies the matching checklist, and structures the manuscript template according to the appropriate reporting guideline. You cannot accidentally use the wrong PRISMA variant.